Modipafant is a potent dihydropyridine PAF (Platelet-Activating Factor) antagonist. PAF is an important inflammatory mediator in asthma. Modipafant is a lipophilic weak base with log D(octanol) 7.4 and pKa of 4.3 and 5.3 respectively. References: Jezequel SG, Uden S, Wastall P. Modipafant, a new PAF antagonist: pharmacokinetics and disposition in rat, dog and man. Xenobiotica. 1996 Sep;26(9):963-75. PubMed PMID: 8893043. 2: Kuitert LM, Angus RM, Barnes NC, Barnes PJ, Bone MF, Chung KF, Fairfax AJ, Higenbotham TW, O'Connor BJ, Piotrowska B, et al. Effect of a novel potent platelet-activating factor antagonist, modipafant, in clinical asthma. Am J Respir Crit Care Med. 1995 May;151(5):1331-5. PubMed PMID: 7735582.

纯度：≥98%

CAS：122957-06-6